Pfizer, Astellas report positive results from trial of Xtandi in non-metastatic castration-resistant disease

Urine test improves non-invasive detection of prostate cancer

A urine test that measures 18 genes associated with prostate cancer provides higher accuracy for detecting clinically significant cancers than PSA and other existing biomarker tests, according to a study published April 18 in JAMA Oncology.

April 19, 2024

Vol.50 No.16

Clinical Roundup

UCLA: Attacking metastatic prostate cancer early with combination treatment improves outcomes

A team of UCLA Health Jonsson Comprehensive Cancer Center investigators has shown the combination of a short course of powerful and intense hormonal therapy with targeted radiation is safe and effective in treating people with prostate cancer that has come back and has spread to other parts of the body.

March 22, 2024

Vol.50 No.12

Clinical Roundup

Plant-based diet tied to improved sexual health during prostate cancer treatment

A diet that limits meat and dairy but is rich in fruits, vegetables, grains, and nuts is linked to less erectile dysfunction, urinary incontinence, and other common side effects seen in prostate cancer patients, a new study shows.

February 16, 2024

Vol.50 No.07

Clinical Roundup

Long-term follow-up pinpoints side effects of prostate cancer treatments

A 10-year follow-up study of nearly 2,500 U.S. men who received prostate cancer treatment will help inform decision-making in terms of treatments and side effects for a diverse population.

January 26, 2024

Vol.50 No.04

Clinical Roundup

Study determines factors affecting decisions regarding active surveillance in low-risk prostate cancer

A study examined the rates of active surveillance use and evaluated the factors associated with selecting this management strategy over surgery or radiation in low-risk prostate cancer, with a focus on underserved Black patients who have been underrepresented in prior studies.

January 26, 2024

Vol.50 No.04

Clinical Roundup

Molecular profiles of tissue plus circulating tumor DNA can better guide cancer care

The current standard of care for identifying targetable mutations in cancer treatment is to conduct molecular profiles on tumor tissue samples, but a study published in JAMA Network Open indicates that adding liquid biopsy testing for circulating tumor DNA mutations increases targetable mutation detection rates.

January 26, 2024

Vol.50 No.04

Pfizer, Astellas report positive results from trial of Xtandi in non-metastatic castration-resistant disease

YOU MAY BE INTERESTED IN

Urine test improves non-invasive detection of prostate cancer

UCLA: Attacking metastatic prostate cancer early with combination treatment improves outcomes

Plant-based diet tied to improved sexual health during prostate cancer treatment

Long-term follow-up pinpoints side effects of prostate cancer treatments

Study determines factors affecting decisions regarding active surveillance in low-risk prostate cancer

Molecular profiles of tissue plus circulating tumor DNA can better guide cancer care

Renew today!

Subscriber content

Login